Tuesday, 28 February 2017

2016 Survey Results

Another year passes and we are round to Rare Disease Day again, this year with the theme of research which seems highly appropriate for me!

I am pleased to publish the results of my fourth HSP survey which I launched in September 2016. Many thanks are due to the 169 people who gave their time and completed the survey - this wouldn't have been possible without you. Most of the respondents were from the USA and the UK, and about a quarter had also completed at least one of my previous surveys.

The text below is a short version of the results. The full version goes into more detail on each of the different elements, with more graphs, tables and detailed breakdowns of different results and factors, and the questionnaire scoring systems. The full analysis can be found here: 
https://drive.google.com/file/d/0BzEoTkR5HCWhSEQ1UElwamVod3c/view?usp=sharing&resourcekey=0-8UrNFT_UZbvcSyvprbNg9A

This analysis is by far my longest yet. Apologies for some readers, the lines on my tables are not behaving themselves this year!

Mobility Analysis
From the answers to the mobility questions it is possible to see which mobility aids are the most regularly used. Around half of respondents use walking sticks/poles/crutches/canes, and similarly, around two fifths of respondents use a wheelchair or mobility scooter. FES is the mobility aid used by the least number of people, with a take-up of around 5%. Broadly these results are similar to those from previous years.

I have devised an “HSP mobility score” which then allows me to cross-reference mobility against the other questions in the questionnaire. The definition of the HSP mobility score is;

  1. No mobility effects
  2. Walks without aids but has some effects
  3. Orthotics/AFO/FES and/or Sticks/Poles/Crutches/Canes some of the time
  4. Sticks/Poles/Crutches/Canes and Frame/Chair some of the time
  5. Sticks/Poles/Crutches/Canes most of the time
  6. Sticks/Poles/Crutches/Canes all of the time
  7. Rollator/Walking frame most of the time
  8. Rollator/Walking frame all of the time
  9. Wheelchair/Mobility scooter most of the time
  10. Wheelchair/Mobility scooter all of the time
The overall results are;

Mobility Aids Used - Overview:
Respondents
Percentage
Mobility Score
Those without aids
30
18%
0-1
Those who use mobility aids some of the time
42
25%
2-3
Those who use sticks most/all of the time
55
32%
4-5
Those who use frames most/all of the time
13
8%
6-7
Those who use chairs most/all of the time
29
17%
8-9

Fatigue
Fatigue is often noted as a symptom of HSP. My 2013 survey showed that 62% of people experienced fatigue as a significant symptom and 30% experienced fatigue as a minor symptom. I wanted to find out more about fatigue.

I could only find one paper on fatigue in HSP, a study from 2015-2016 which examined non-motor symptoms in people with SPG4 in Brazil – Non-motor symptoms in patients with hereditary spastic paraplegia caused by SPG4 mutations, by Katiane Servelhere and others. (https://www.ncbi.nlm.nih.gov/pubmed/26806216) This study used the Modified Fatigue Impact Scale for fatigue and reported that “patients with SPG4-HSP had more severe fatigue than controls (MFIS: 31.3±14.9 vs 14.9±15.4, p<0 .001="" o:p="">

There has also been research undertaken in assessing fatigue in Multiple Sclerosis (a common misdiagnosis for HSP) including development of the Neurological Fatigue Index. The Brief Fatigue Inventory also appears to be used in a number of different conditions, including cancer. Since all of these are available in a short-form version I chose to ask all three questionnaires, and would then be able to test if one is more suited to HSP. The questionnaire asked respondents to complete:
  • Neurological Fatigue Index (NFI-MS, a 9 question survey)
  • Modified Fatigue Impact Scale (MFIS-5, a 5 question survey)
  • Brief Fatigue Inventory (BFI, a 9 question survey)
Neurological Fatigue Index - MS
The Neurological Fatigue Index (NFI-MS) asks people to select how much they agree with each of 9 questions, selecting from; Strongly Disagree, Disagree, Agree and Strongly Agree. The nine questions are:
·          Sometimes, I lose my body strength
·          Sometimes, I really have to concentrate on what are usually simple things
·          The thought of having to do something often puts me off doing it
·          By the end of the day I'm shattered
·          If I've overdone things, I know about it the next day
·          I soon become weak after physical effort
·          Resting allows me to carry on
·          I can become weak even if I've not been doing anything
·          When I awake in the morning, I feel unrefreshed

Details of the survey can be found here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834659/. Each question is scored depending on the answer selected, where Strongly Disagree =0, Disagree =1, Agree =2 and Strongly Agree =3. The overall score is the sum over the nine questions, and therefore can range between 0 (answering ‘strongly disagree’ to all questions) and 27 (answering ‘strongly agree’ to all questions).

The table below shows the results.

Mobility Score
Respondents
Minimum Score
Average Score
Maximum Score
0-1
30
3
16.6
26
2-3
41
7
15.4
24
4-5
52
9
17.5
27
6-7
13
9
17.0
22
8-9
27
10
19.5
25

These results show that the average and maximum scores are generally independent of mobility although 
the average score rises slightly with decreased mobility. Those who do not use mobility aids (mobility score 0 or 1) have lower minimum scores than those who use mobility aids (mobility score 2 or more).


The answers to the questions allow the different fatigue factors to be examined. Overall, the three statements which the most people agreed with were “If I've overdone things, I know about it the next day” (81% agreeing), “Resting allows me to carry on” (79% agreeing) and “I soon become weak after physical effort” (78% agreeing). Overall, the three statements with he least people agreeing with were “sometimes, I really have to concentrate on what are usually simple things” (60% agreeing), “When I awake in the morning, I feel unrefreshed” (62% agreeing) and “I can become weak even if I've not been doing anything” (69% agreeing).

The factors do change with level of mobility. For those who do not need aids (mobility score 0-1). Most people agree with “I soon become weak after physical effort” (80% agree) and fewest agree with “The thought of having to do something often puts me off doing it” (53% agree). At the other end of the mobility score, those in wheelchairs all or most of the time (mobility score 8-9) most people agree with “By the end of the day I'm shattered” and “I can become weak even if I've not been doing anything” (93% agree with each) and fewest agree with “When I awake in the morning, I feel unrefreshed” (70% agree). 

Modified Fatigue Impact Scale 5
There are two versions of the Modified Fatigue Impact Scale (MFIS) scale, a full questionnaire with 21 questions and a shorter version with 5 questions. The five questions are those from the full survey whose answers correlated most strongly with the overall 21 question survey score. The full 21 questions on this survey are themselves a subset of the Fatigue Impact Scale. The Modified Fatigue Impact Scale asks people to select how often fatigue has affected them, selecting from; Never, Rarely, Sometimes, Often and Almost Always. The five questions are:
·          I have been less alert
·          I have been limited in my ability to do things away from home
·          I have had trouble maintaining physical effort for long periods
·          I have been less able to complete tasks that require physical effort
·          I have had trouble concentrating

Details of both versions of the MFIS survey can be found here (along with a number of other questionnaires associated with Multiple Sclerosis): http://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/MSQLI_-A-User-s-Manual.pdf Each question is scored depending on the answer selected, where Never =0, Rarely =1, Sometimes =2, Often =3 and Almost Always =4. The overall score is the sum over the five questions, and therefore can range between 0 (answering ‘never’ to all questions) and 20 (answering ‘almost always’ to all questions).

The questions have been grouped to cover three key areas of fatigue; Physical (the two ‘maintaining physical effort’ questions), Cognitive (the ‘less alert’ and ‘trouble concentrating’ questions) and Psychosocial (the ‘limited in my ability’ question).

The table below shows the results.
Mobility Score
Respondents
Minimum Score
Average Score
Maximum Score
0-1
27
0
11.0
20
2-3
39
0
9.7
17
4-5
53
2
12.7
19
6-7
11
2
11.9
19
8-9
27
7
14.1
18

These results show that the average and maximum scores are generally independent of mobility although the average score rises slightly with decreased mobility. It is only those in wheelchairs all or most of the time (mobility score 8 or 9) who consistently have a higher minimum score. 

The MFIS scale allows us to look at the different areas of fatigue. The overall maximum score of 20 would comprise a score of 8 each from Physical and Cognitive sections and a score of 4 from the Psychosocial section, and the graph below splits the average score into the three areas:

This graph shows that the physical questions make the greatest contribution to the fatigue score across all levels of mobility, scoring slightly more than the cognitive questions. The psychosocial question contributes the least, and would still contribute the least if its score were doubled to give it equal weight to the physical and cognitive questions. From this, we can see that both physical and cognitive factors play a part in the fatigue of people with HSP.

The analysis of respondents with SPG4 shows results similar to the full dataset, whereas those with SPG7 tend to have a higher level of fatigue.

The MFIS-5 questionnaire shows similar results to the Brazil results, in that the physical score contributes the most to the overall fatigue level and the psychosocial score contributes the lowest level. In the full MFIS questionnaire there are 9 physical questions (with a maximum score of 36), there are 10 cognitive questions (with a maximum score of 40) and there are 2 psychosocial questions (with a maximum score of 8).


Brief Fatigue Inventory
The Brief Fatigue Inventory (BFI) has 2 sections. The first section has three questions and asks people to rate their fatigue on a scale between 0 and 10 where 0 = ‘No fatigue’ and 10 = ‘As bad as you can imagine’. They are asked to rate their fatigue right now, their usual level of fatigue and their worst level of fatigue. They are then asked to rate how their fatigue has interfered with six items using a scale between 0 and 10 where 0 = ‘Does not interfere’ and 10 = ‘Completely interferes’. The six items are:
·          General activity
·          Mood
·          Walking ability
·          Normal work (both outside home and daily chores)
·          Relations with other people
·          Enjoyment of life

Details of the BFI are here:  http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0142(19990301)85:5%3C1186::AID-CNCR24%3E3.0.CO;2-N/full. The questionnaire is scored by taking the average of the scale score of the nine items, and therefore can range between 0 (score 0 to all questions) and 10 (score 10 to all questions).  The table below shows the results.
Mobility Score
Respondents
Minimum Score
Average Score
Maximum Score
0-1
26
0.7
5.5
9.0
2-3
40
0.3
4.8
8.2
4-5
54
2.0
6.0
9.3
6-7
12
0.6
4.8
7.3
8-9
27
1.7
6.5
9.4

These results show that the average and maximum scores are generally independent of mobility although t
here is a slight upward trend on the average score with decreased mobility. There is no clear pattern in the minimum score.

The scale has been interpreted within the previous Wiley link, and a number of different classifications are made for mild, moderate and severe fatigue in cancer patients, as shown in Table 4 in the link. Since the average score is unlikely to be a whole number, I am using the following similar definitions;
·          Score less than 3 – Mild fatigue
·          Score between 3 and 7 –  Moderate fatigue
·          Score greater than 7 – Severe fatigue.

The table below shows the number of respondents with mild, moderate and severe fatigue, along with the proportion of that mobility score group:
Mobility Score
Respondents
Mild Fatigue
Moderate Fatigue
Severe Fatigue
0-1
26
3 (12%)
15 (58%)
8 (31%)
2-3
40
6 (15%)
31 (78%)
3 (8%)
4-5
54
6 (11%)
28 (52%)
20 (37%)
6-7
12
2 (17%)
9 (75%)
1 (8%)
8-9
27
1 (4%)
15 (56%)
11 (41%)
Overall
159
18 (11%)
98 (62%)
43 (27%)

This table shows that between around 90% of people with HSP have moderate or severe fatigue.



Fatigue Summary
Of the people which answered the fatigue questions, 126 said that their fatigue at the time they answered the questions was similar to their normal level of fatigue. 7 people said their fatigue was better than normal and 36 said that their fatigue was worse than normal. This may suggest that the results of this survey present a slightly more adverse picture than ‘normal’ for the fatigue levels of people with HSP.

166 respondents answered the question about which fatigue survey they preferred. 132 said that they had no clear preference for one of the surveys. Of the 34 respondents who expressed a preference 19 preferred the NFI questionnaire, 9 preferred the MFIS-5 questionnaire and 6 preferred the BFI questionnaire. There were people from across the range of mobility scores who preferred the NFI and MFIS-5 questionnaires. Whereas people who preferred the BFI tended to have less reliance on mobility aids, with mobility scores between 1 and 5.

The average scores for each of the three fatigue questionnaires show that fatigue is generally independent of mobility. Those respondents who do not use mobility aids tended to score slightly lower fatigue levels than those who use mobility aids all or most of the time, but there is a wide spread of data, and there are some who do not use mobility aids who have higher levels of fatigue than those who use mobility aids all the time.

The MFIS-5 questionnaire shows that whilst the physical factors of HSP contribute the most to fatigue there is also an important cognitive aspect. Those with SPG7 tend to have a higher level of fatigue than those with SPG4. The BFI questionnaire shows that around 90% of people with HSP have moderate or severe fatigue.  


Bladder Issues
There have been a number of papers examining bladder issues in those with HSP. Bladder dysfunction in hereditary spastic paraplegia: a clinical and urodynamic evaluation, by Fourtassi et al in 2012 (Pubmed ID 22289900), reports urgency being the most common complaint affecting 72% of people, followed by increased frequency (affecting 66%), incontinence (affecting 55%) and hesitancy (affecting 52%). The study examined 29 patients and was carried out in France. These results are similar to Bladder dysfunction in hereditary spastic paraplegia: what to expect?, by Braschinsky et al in 2010 (Pubmed ID 197226407), which reports incontinence being the most common symptom, affecting 69%, followed by hesitancy (affecting 59%), increased frequency (affecting 55%) and urgency (affecting 51%). The study examined 38 patients with urinary symptoms out of 49 patients. The study was carried out in Estonia.

The various texts on HSP often describe having overactive bladders (OAB). I reviewed different short form questionnaires for overactive bladders, and found the International Consultation on Incontinence Modular Questionnaire (ICIQ). There are a number of different questionnaires for different aspects of different pelvic problems, and they have the objective of developing validated international standard questionnaires for wide use.

They have an overactive bladder survey http://www.iciq.net/ICIQ.OABmodule.html which “provides a brief and robust measure to assess the impact of symptoms of overactive bladder on quality of life and outcome of treatment.” There are four questions in this questionnaire, and users select their answers from pre-determined answers.

The scale does not appear to show what a normal score would be. However, this report (http://bmcurol.biomedcentral.com/articles/10.1186/s12894-015-0009-6) uses the questionnaire to examine stress levels within a population with overactive bladders, carried out by Henri Lai (et al) in St Louis, USA. They had a range of age matched controls who had an average score of 2.0, plus or minus 1.5. This suggests that a score of 3-4 could be used to mark the start an overactive bladder (OAB).

Of note, that paper reports that “OAB patients reported psychological stress levels that were …. significantly higher than healthy controls. There was a positive correlation between perceived stress levels and urinary incontinence symptoms, and its impacts on quality of life among OAB patients.”

Overall score
These questions were answered by 165 respondents. The following table gives a summary of the results;
Mobility Score
Respondents
Minimum Score
Average Score
Maximum Score
0-1
30
0
5.4
10
2-3
41
0
4.4
14
4-5
53
0
5.6
12
6-7
13
0
7.5
14
8-9
28
1
7.1
16
Overall
165
0
4.6
16

This shows that there are people in each mobility band who do not have any bladder symptoms, and there are people within each mobility band who have bladder symptoms. Given that the score ranges between 0 and 16, for the purposes of this analysis I am grouping scores as follows;
·          3-6 = mild effects, things occur “occasionally”,
·          7-10 = moderate effects – things occur “some of the time”
·          At least 11 = severe effects – things occur “most” or “all” of the time.

Using this scoring system the results show:
Mobility Score
Respondents
No effects
Mild effects
Moderate effects
Severe effects
0-1
30
5 (17%)
14 (47%)
11 (37%)
0 (0%)
2-3
41
14 (34%)
17 (41%)
8 (20%)
2 (5%)
4-5
53
9 (17%)
29 (55%)
11 (21%)
4 (8%)
6-7
13
1 (8%)
4 (31%)
8 (38%)
3 (23%)
8-9
28
5 (18%)
9 (32%)
8 (29%)
6 (21%)
Overall
165
34 (21%)
73 (44%)
43 (26%)
15 (9%)

This shows that around two thirds of people with HSP have no or mild bladder effects, and around one third have moderate or severe effects. There is a general trend that the milder effects tend to be with those with lower mobility issues, and the bladder effects tend to be more severe with those with higher mobility issues.

The results of the bladder questions appear to be broadly in line with two previous studies examining bladder issues in people with HSP, from France and Estonia.
·          The key bladder symptoms appear to be frequency and incontinence, affecting the greatest proportion of respondents.
·          Passing urine 4 to 6 times per day is normal. Just under half of respondents do this, just over half go more often.
·          Passing urine no more than once a night is normal, two thirds of respondents do this, one third go more often.
·          A third of respondents have to rush to the toilet most or all of the time, with a further quarter having to rush sometimes. Two fifths do not have to rush.
·          Urine leakage most or all of the time occurs in one fifth of respondents, a further third have this sometimes. Overall, half of respondents are affected by incontinence, one fifth of respondents are not affected and three tenths are affected occasionally.
·          The level of bother is generally above that expected by symptoms. Many respondents are bothered quite a lot by these symptoms.

Bowel Issues
There do not appear to be any papers examining bowel issues in those with HSP. Several reports describe bowel or sphincter issues, but from the abstracts available none appear to quantify this.

When reviewing the short form questionnaires for overactive bladders I noted the International Consultation on Incontinence Modular Questionnaire (ICIQ) included a questionnaire on the bowel. The website http://www.iciq.net/structure.html indicates that the bowel surveys are not finalised, however there are several other references to the ICIQ-B survey, e.g. https://www.kingstonmaternity.org.uk/media/187024/bowl-function-questionnaire-iciq-b-uk-english-.pdf.

There are twenty two questions in this questionnaire, with users selecting their answers from pre-determined lists. I decided that I would ask nine of these questions in order to get a picture of bowel function, following the general format of the overactive bladder questionnaire. The questions I selected were:
·          Q3A/3B: On average how many times do you open your bowels in 24 hours?
·          Q4: How often do you open your bowels during the night from going to bed to sleep until you get up in the morning?
·          Q5: Do you have to rush to the toilet when you need to open your bowels?
·          Q6: Do you use medications (tablets or liquids) to stop you opening your bowels?
·          Q7: Do you experience pain/soreness around your back passage?
·          Q8: Do you experience any staining of your underwear or need to wear pads because of your bowels?
·          Q13: Do you have bowel accidents when you have no need to open your bowels?
·          Q16: Do you need to strain to open your bowels?
·          Q23: Overall, how much do your bowels interfere with your everyday life?

Overall score
These questions were answered by 155 respondents. The following table gives a summary of the results;
Mobility Score
Respondents
Minimum Score
Average Score
Maximum Score
0-1
28
2
8.6
16
2-3
39
4
8.0
15
4-5
51
4
9.8
20
6-7
11
5
10.4
16
8-9
26
5
11.8
19
Overall
155
2
9.5
20

This shows that there are people in each mobility band who have no symptoms or minor symptoms, and there are people within each mobility band who have several symptoms. The minimum and average scores both generally increase as mobility issues increase. Given that the score ranges between 2 and 37, for the purposes of this analysis I am grouping bowel scores as follows;
·          5-11 = mild effects – things occur “rarely”
·          12-20 = moderate effects – things occur “some of the time”
·          At least 21 = severe effects – things occur “most” or “all” of the time

Using this scoring system the results show:
Mobility Score
Respondents
No effects
Mild effects
Moderate effects
Severe effects
0-1
28
5 (18%)
15 (54%)
8 (29%)
0 (0%)
2-3
39
3 (8%)
29 (74%)
7 (18%)
0 (0%)
4-5
51
2 (4%)
32 (63%)
17 (33%)
0 (0%)
6-7
11
0 (0%)
8 (73%)
3 (27%)
0 (0%)
8-9
26
0 (0%)
12 (46%)
14 (54%)
0 (0%)
Overall
155
10 (6%)
96 (62%)
49 (32%)
0 (0%)

This shows that around three fifths of people with HSP have mild bowel effects, and around one third have moderate effects. A few people have no effects at all, and no people showed severe effects. There is a general trend that the milder effects tend to be with those with lower mobility issues, and the bowel effects tend to be more severe with those with higher mobility issues.

·          The key bowel symptoms are urgency and hesitancy, affecting the greatest proportion of respondents.
·          Opening your bowels between three times a week and three times a day is normal. 95% of respondents do this, 5% go more often.
·          It is not normal to open your bowels during the night. Nearly 90% of respondents do this, almost 10% need to go in the night.
·          A sixth of respondents have to rush to the toilet most or all of the time, with a further third having to rush sometimes. Half do not have to rush.
·          A third of people with HSP have to strain to open their bowels most or all of the time, with a further third having to strain sometimes. One third do not need to strain.
·          Some people have to both rush to the toilet and strain. 6 respondents have to rush and strain all or most of the time.
·          Wearing pads and/or staining underwear more than once a month occurs in about a quarter of respondents. Less than three fifths of respondents do not have this problem, and less than one fifth have this less than once a month.
·          One fifth of respondents have bowel accidents ‘sometimes’ of which only a small number have this ‘most of the time’ or ‘always’. More than half do not have this problem, and a quarter have it rarely.
·          The level of bother generally increases in line with symptoms. Those with more symptoms tend to have higher levels of bother.


HSP Information Sources
I also asked respondents where they got their information on HSP. 160 people gave answers to these questions, although some answers were partial. Most people get their information about HSP from social media, doctors and neurologists. Medical websites, support groups, physiotherapists and friends/family with HSP form another important group of information sources.

The sources which people regarded as most trustworthy were neurologists, support groups and physiotherapists. Social Media and friends/family with HSP form another important group. Of sources used by more than half of respondents, the ones with people being most unsure were doctors and other medical professionals.

Overall; people need to be selective in what they believe on social media – and check out the author. Support groups can be a good source of information. People may need to work on relationships with doctors so they understand people’s situations better. Talking about your situation with friends/family with HSP may be useful for you and them. 

Like this? in previous years:
Overview of all my surveys: http://hspjourney.blogspot.co.uk/p/my-on-line-resarch.html
2015: Modifications at home, depression, quality of life: http://hspjourney.blogspot.co.uk/2016/02/2015-survey-results.html
2014: Medication, exercise & relaxation: http://hspjourney.blogspot.co.uk/2015/02/2014-survey-results.html

2013: Symptoms and misdiagnosis: http://hspjourney.blogspot.co.uk/2014/02/hsp-survey-results.html

Sunday, 12 February 2017

Physical Activity in Rare Conditions Collaboration (PARCC) Meeting

Right at the end of January the HSP support group was invited to attend the Physical Activity in Rare Conditions Collaboration (PARCC) Meeting in Cardiff. I attended with Ian Bennett. The group organising the meeting are just starting a piece of research looking at how to promote/support physical activity in people with rare conditions.

The research is being run by a group of researchers with an interest in rehabilitation for people with rare neurological conditions from three universities in the UK - Dr. Gita Ramdharry from Kingston/St George’s University,  Prof. Monica Busse from Cardiff University and  Prof. Jon Marsden from Plymouth University.

HSP was one of five conditions invited to the meeting, along with Muscular Dystrophy (represented by Muscular Dystrophy UK), Ataxia (represented by Ataxia UK), Huntingtons Disease (represented by the Huntingtons Disease Association) and Progressive Supranuclear Palsy (represented by the Progressive Supranuclear Palsy Association).

They have conducted initial research with Huntingtons Disease which has shown the importance of structured support and information to allow people to find ways of keeping physically active that they enjoy and helps them to manage their condition. You can read about this here: https://www.neurology-central.com/2016/05/12/11072/,  here: http://blogs.cardiff.ac.uk/active-huntingtons-disease/physical-activity-in-huntingtons-disease-ehdn2016/ and here: http://www.sciencedirect.com/science/article/pii/S1353802016302437. This research shows that "a short-term exercise intervention is safe, feasible, and leads to significant improvements in fitness and motor function in people with HD"

The group of researchers has experience working with neurological conditions, physiotherapy and exercise, and they are looking to expand this concept to cover more rare conditions so that there is a sufficiently large program of work to bring people together, to have more study power and to give stronger, more conclusive results.

The initial starting point of the discussion was on the challenges around using physical activity as a treatment. The first step is to define what is meant by "physical activity" - this means different things to different people, and whilst it might mean specific exercises/activities to some, it might be more like just getting out of the house more often to others.

There has been a history of poor advice given, people have differing physical challenges, there are varying issues with access to facilities and costs, the support from professionals and/or carers varies, along with issues on motivation, choice and the time taken. Essentially the group is trying to get a good handle on these issues to develop a solution/intervention to support people.

Trial design was mentioned briefly, including this article on how you can design randomised trials for smaller populations: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0722-3/open-peer-review.

Part of the day was spent with each charity describing the main features of each of the conditions, and taken together there are many strong similarities - principally that they all have a long term gradual deterioration in mobility, there are often mood changes with the conditions and day-to-day variation can be bigger than the long term changes. There were also some subtle differences, for example those with PSP and HD often are better in the afternoon, whereas some with HSP are better in the morning.

An interesting aspect was talking about how to get physical activity into the daily routine. With some the benefit might greater getting the activity as a routine before it is needed, so that it can be practised before it becomes difficult. Activities will need to adapt to peoples changing conditions - for example activity for someone who can still walk may be different from someone who spends most of their time in a wheelchair. There are also a range of personal factors which need to be considered - some people are happy to go to the gym, whereas others are more self conscious and would dislike going. Some people prefer to undertake activity in a group, whereas others prefer to do it alone.

Another topic is how the activity would be measured. The group are keen that the activity can be measured easily, and this might be by indirect methods - how often people leave their home or how their quality of life changes rather than how the specific activity might be assessed in the clinic.

The group are keen to develop a tool that is individualised, accessible when needed, meaningful, and focuses on what is trying to be achieved rather than the specifics of what could be done. Overall, I thought it was a really useful day, and I'm looking forward to the next stage.

Things which came up, to look up another day include:
Life Space Diaries: eg http://journals.sagepub.com/doi/pdf/10.1177/073346489901800404
Health Unlocked Forum: https://healthunlocked.com/
Goal attainment scaling: https://en.wikipedia.org/wiki/Goal_Attainment_Scaling
COM-M models: http://www.behaviourchangewheel.com/about-wheel


Thursday, 26 January 2017

Intermittent Self-Catheterisation

Last week a nurse from the local incontinence came to visit, following a referral from my GP as a result of their letter from the HSP clinic in London. The main purpose of the visit was to measure my PVR (post voidal residual), but also for me to find out more about Intermittent Self-Catheterisation, or ISC for short.

It seems that ISC is a solution that some people go for with their bladder issues, and that has been a comment made in a few survey responses. I wanted to find out about this so that when it comes to making that decision myself I've got some knowledge.

Intermittent Self-Catheterisation

I was given a LoFric guide "Living with LoFric, A guide to ISC for men". I cant seem to find that brochure on line, but there are plenty of other similar ones on their site: http://www.wellspect.co.uk/For-users/Bladder-management/Getting-started-with-catheterization/CIC-Instructions-and-guidelines

The bladder collects waste from the kidneys. The kidneys produce this continuously, and it is collected in the bladder so you can pass it when you need to. Messages are sent from the bladder to the brain to indicate that bladder needs to be emptied, and then messages are sent back down to both contract the bladder muscle and relax the sphincter muscle, which starts off the flow through your urethra. The process should continue until the bladder is completely empty.

A few basics are described - normally the bladder should not contain more than 350-400ml. Normally we urinate about 4 to 6 times a day and occasionally at night.

The ISC is a tube which is inserted along the urethra and into the bladder, which then allows your urine to drain. It indicates that it may take a long time for the bladder to drain. Advice is given if you find it difficult to insert the catheter (cough or try to pass urine), how to stop dips/drops (put your finger over the end of the catheter).

Advantages to ISC are given;
  • protects kidneys
  • reduces risks of unrinary tract infections (UTIs)
  • improve quality of life
  • improve comfort
  • reduce risk of complications and disease
  • improve continence
  • reduce residual urine
  • increase autonomy
  • not interfere with your sex life
It seems that there are a number of different products, and it is important to select the right option, length and diameter. The LoFric catheters have a hydrophilic coating which creates a very wet and slippery surface when activated by water, which minimises friction. Other catheters use a gel instead.

It is recommended that catheterising is done in clean and suitable facilities, but notes that such conditions are not always available, and some catheters include integrated sterile water and handling aids - useful if you're not able to wash your hands before starting.

My PVR

Back to the nurse visit. She came armed with an ultrasound scanner. As might be expected I was unable to pass urine whilst she was here. She measured the amount of liquid in my bladder to be around 250ml, a couple of hours after using the toilet. I went to the toilet about half an hour after she left and measured my urine volume - about 250ml. My conclusion is that I dont have a high PVR, and therefore at a low risk of infection, so no need to alter what I'm doing at the moment.

Monday, 9 January 2017

Daily living scale study participation

The Rare Diseases Clinical Research Network or RDCRN is a US organisation designed to advance medical research on rare diseases by providing support for clinical studies and facilitating collaboration, study enrollment and data sharing.  https://www.rarediseasesnetwork.org/whoweare/index.htm. 

Within this there are a number of rare disease research groups, including CReATe - Clinical Research in ALS and Related Disorders for Therapeutic Development. This group includes:

  • sporadic and familial forms of amyotrophic lateral sclerosis (ALS), 
  • frontotemporal dementia (FTD), 
  • primary lateral sclerosis (PLS), 
  • hereditary spastic paraplegia (HSP), and 
  • progressive muscular atrophy (PMA). 


The goals of the CReATe consortium are to advance therapeutic development for this group of neurodegenerative disorders through study of the relationship between clinical phenotype and underlying genotype, and also through the discovery and development of biomarkers. https://www.rarediseasesnetwork.org/cms/create


One of their current projects is to develop A Patient Centric Motor Neuron Disease Activities of Daily Living Scale for all of their diseases.

The text below is from their website, describing the study. If you have HSP (or one of the other diseases) you can take part. You answer a monthly questionnaire by email for a year, taking 10-20 mins each time. If you want to take part, sign up! I've done this.




Study Summary

The purpose of this study is to learn about rates of disease progression in patients with motor neuron diseases, as reported by the patients while they are outside of clinic. Another purpose of this study is to learn about clinical characteristics that patients report influence this rate of progression.

Background

  1. What is the feasibility, ease of use, and rates of MND progression of a new patient-reported cactivities of daily living scale (PADL-ALS)?
  1. Can patient-reported clinical features predict disease progression using the PADL-ALS?
  1. How will rates of progression seen using the PADL-ALS compare to previously reported disease progression models described for the ALSFRS-R?

About This StudyTargeted Enrollment

Be an individual with one of the following:
  • ALS (Amyotrophic Lateral Sclerosis)
  • ALS-FTD (Amyotrophic Lateral Sclerosis - Frontotemporal Dementia)
  • PLS (Primary Lateral Sclerosis)
  • PMA (Progressive Muscular Atrophy)
  • HSP (Hereditary Spastic Paraplegia)

    or
  • Other motor neuron disease
You cannot provide informed consent and complete survey

How to participate:


Functional rating scales have become the standard primary outcome measure for clinical trials of neurodegenerative diseases. The ALS Functional Rating Scale-Revised (ALSFRS-R) was designed to assess the ability of ALS patients to perform activities of daily living and to detect functional changes during clinical trials. The ALSFRS-R is quickly administered by research personnel or study staff (ten minutes) and is a rating scale that assesses capability and independence in 12 functional activities. The ability to use a patient-reported tool like the ALSFRS-R to assess patient function between clinic visits from the home would be a powerful new tool for clinicians to monitor the effect of interventions including: medications, orthotic devices, and respiratory or feeding support. In addition, the usefulness of a scale like the ALSFRS-R in the full range of MND is not known. We developed a new patient-reported survey which incorporates many of the key elements of the ALSFRS to be used by MND patients in between patient visits.

 The research questions are:
  1. What is the feasibility, ease of use, and rates of MND progression of a new patient-reported cactivities of daily living scale (PADL-ALS)?
  2. Can patient-reported clinical features predict disease progression using the PADL-ALS?
  3. How will rates of progression seen using the PADL-ALS compare to previously reported disease progression models described for the ALSFRS-R?
About This Study
This is a prospective 12-month study of patients with MND enrolled in CReATe Connect, an RDCRN Contact Registry. Participants will be asked to complete the survey every month for 1 year.
The survey will contain questions about participants’ diagnosis (such as age when symptoms started, where first symptoms occurred) and functional status (things like walking, eating, dressing, breathing). We will ask participants to update their functional status survey (15 questions) monthly for 1 year. Participants may choose to skip any question(s) that make them feel uncomfortable. It should take approximately 20 minutes to complete the survey the first time, then 10-15 minutes for each follow up survey.
Targeted Enrollment
To be eligible to participate, you must:
  • Be an individual with one of the following:
    • ALS (Amyotrophic Lateral Sclerosis)
    • ALS-FTD (Amyotrophic Lateral Sclerosis - Frontotemporal Dementia)
    • PLS (Primary Lateral Sclerosis)
    • PMA (Progressive Muscular Atrophy)
    • HSP (Hereditary Spastic Paraplegia)
  • or
    • Other motor neuron disease
You are not eligible to participate if:
  • You cannot provide informed consent and complete survey
How to participate:
If you have not done so already, please join CReATe Connect, a Contact Registry that has been established through the RDCRN! We will invite individuals in CReATe Connect to participate in this study.

Tuesday, 27 December 2016

Review of 2016

Another year has past and its time for me to reflect what has happened during the year.

Knowledge

This year I have learnt a lot. I have been to two conferences - the drug re-purposing one run in London by Findacure in February and the Ataxia/HSP one run by the Spatax network in Paris in April. Lots of bits of information has gone in, and I've been talking with various researchers and professionals at both conferences. I've also kept a brief eye out on the news reported by the US and Australian HSP groups.

Symptoms

Overall, I think that 2016 has been fairly stable. I'd been thinking that things were getting gradually worse, but my appointment at the HSP clinic suggested that my gait might be better. The various stretches, in-soles, bladder medication and Pilates mean things aren't changing quickly. Looking at my charts I think I've been a bit less depressed and with less fatigue than previous years, I might be spotting the return of more bladder/bowel issues though.

For a while during the year I logged my sleep patterns, and I'm fairly confident that my fatigue is predominantly due to lack of sleep, rather than any HSP issues.

This Blog

As last year, the readership of this blog continues to increase. I'm continuing to get year on year reader growth. My audience remains broadly the same (predominantly US, UK, Russia, Ukraine, France, Germany, Turkey, Canada). The most popular posts continue to be the results of my survey, the various presentations/posters given at meetings and my general posts on research and particular HSP symptoms.

I've had various comments made that people appreciate reading what I have to say, which I'm very pleased to receive and gives another reason why this is a worthwhile thing to do. Thank you to anyone that makes a comment or connects up with me in some other way.

Survey

I was pleased that the results of my 2015 survey got similar levels of readership to my 2013 and 2014 surveys, confirming that these are of use and interest to people, and backing up my decision to do one each year, this year seeking opinions on matters to survey from others. I was very pleased to present the results of my first three surveys at the HSP meeting in Paris.

I'll follow the same path for the 2016 survey - analysis will start in the new year so I can analyse, write up and publish on 28th Feb - Rare disease day. This survey already has more responses that my other surveys, and there are still a few more days when I'll be taking answers!

Community Contribution

HSP Community activities for 2016 included:

  • Attending the drug re-purposing and HSP conferences on behalf of the UK Support Group.
  • Using my network (thats you!) to unlock HSP on the Re(act) community
  • Being an active member of the UK Support Group committee.
  • Publicising my companies volunteer days benefit by reporting what I've used them for.
  • Seeking out other on-line HSP communities principally to spread the word of my survey
  • Continuing this blog and posting/discussing HSP things on twitter.

I reflect that there are opportunities for better communication between similar condition support groups, to make the journey of mis-diagnosis potentially easier.

Tuesday, 20 December 2016

How far does my blog reach?

One of the questions I wonder about is where in the world do people live who read my blog. Blogger statistics give me the top 10 countries where people have clicked through to this blog, and I've been keeping track of this, and you can see this tracking on the blog statistics page http://hspjourney.blogspot.co.uk/p/blog-statis.html. My general observation was that readers are predominantly in the UK and US, and there is a reasonably consistent set of other countries where there are readers, frequently being in the top 10 on a monthly basis. Other countries do pop up on a weekly or daily basis, but there didnt seem to be much of a pattern.

Why do I ask this? Most of the HSP groups that I'm aware of are in the UK, US, Europe and Australia. There are a few groups from other parts of the world on Facebook. I'm trying to share my blog as far as I can, and I was wondering which other websites might be worth my visiting. A couple of years ago I found this link:
http://www.smartplanet.com/blog/bulletin/map-the-countries-where-google-and-facebook-dont-rule-the-web/31343 with data from 2013 which shows that Google and Facebook "rule the world" as far as most frequently visited websites go. I've not found an updated version of this map, but the late 2016 position for global websites is here: http://www.alexa.com/topsites and you can see that YouTube is in position 2. My initial thought was that I've got Google and Facebook covered - and its just a question of making sure I'm well searchable!

In discussion with colleagues at work the other month we were discussing Google Analytics, and I enabled that on this blog back in April 2016. This gives a much more comprehensive set of data, and I'm looking to work out how to integrate this information with the Blogger statistics for my long-term tracking.


Headlines are that since April 2016:

25% of my readers are return visitors and 75% are viewing the blog for the first time. There have been over 2000 individuals view the blog in that time, spending on average 2 minutes to read 3 pages.

The top 10 countries are similar to that shown by Blogger (percentage is number of times visited):
1. United Kingdom (33.55%)
2. United States (23.83%)
3. Russia (5.44%)
4. Canada (4.56%)
5. Brazil (3.94%)
6. Australia (3.80%)
7. France (3.55%)
8. Netherlands (2.16%)
9. Italy (2.06%)
10. Belgium (1.57%)

Overall there have been readers from 75 countries. I've had readers from pretty much every European country, the majority of the Americas, Oceania, and Asia, and perhaps a fifth of Africa. There are 26 countries where average time spent reading the blog is more than 1 minute.

Most visitors arrive via a search engine (34%), a link from another site (23%), visiting directly (23%) or through social media (19%). The other site links include the US, UK and Australian group websites (sp-foundation.org, hspgroup.org and hspersunite.org.au) in the top 5, and a few of the European groups a bit further down the list. The social media top 3 are Facebook, Blogger and Twitter,

Conclusions

My blog does get quite far around the world, but there are some corners of the world where there are people with HSP where I dont know how they get their information. I'd welcome websites/info if you know any other groups than these: http://hspjourney.blogspot.co.uk/2013/10/groups-around-world.html

A big thank you to all readers, wherever you are in the world!


Friday, 11 November 2016

Clinic Visit, Physio, Symptoms and Survey Update

Clinic Visit

Back at the end of September I went for an appointment at the HSP clinic at the National Hospital in London. This was very useful. We reviewed my symptoms and treatments, and made the following observations:

Gait 

The view was that my gait has improved since my previous clinic appointment (May 2014 - http://hspjourney.blogspot.co.uk/2014/05/hsp-clinic-visit.html). This was a bit of a surprise, since I've been noticing some general deterioration in my gait recently. We discussed that the improvement is probably because of my physio, stretches and wearing the insoles (my referral for these came from this visit), and actually they have helped me quite a bit - it was just that I didnt notice the initial improvements from this. My conclusion is that I dont have a dataset to measure this against.

We discussed spasticity medication briefly. There is no need for me to start taking this yet, and we'll review again next year. Generally, the first one to try is Baclofen, and I would start on a low dose, increasing gradually until we saw some benefit.

MRI

I've not had an MRI scan so far, and there is a request for this in the letter to my GP. An adventure for 2017 no doubt. I understand that an MRI scan can be used in the diagnosis in order to rule out other possibilities, but the MRI scan will provide a marker to see any deterioration in the spinal cord.

Everything else!

We talked briefly about fatigue - not a big problem at the moment, bladder control - no need to have a post-void residual (PVR) at the moment as my medication has helped with the urgency. If my problems return then it might be time to start self-catheterisation. PVR is measuring the amount of urine left in the bladder after having a wee - probably done with ultrasound. During 2016 my medication changed from Detrusitol to Neditol, but these have the same active ingredient - tolterodine. We also mentioned my AFO's briefly, but not my Pilates.

Conclusion:

I need to keep on with the stretches.

Physio

I also had another appointment with the physio as well - a new lady as my previous physiotherapist has retired. We went through my stretches and I got a few more tips to refine the ones I already do, and a couple of new things to try.

Cycling Monitoring

I've now moved into the world of monitoring my cycling. I have signed up to Strava and use my phone to track my cycling to and from work. My aim, over the long term, is to track any gradual changes in speed/time as a measure of change in spasticity. If anyone wishes to follow me, they're welcome to https://www.strava.com/athletes/18331670!

Survey Update

I'm now about half way through my survey collection, I've about 100 results, predominantly from the UK and USA. Thanks to those who have completed so far. If you can spare 15-20 mins I'd be very pleased for some more responses. http://hspjourney.blogspot.co.uk/2016/09/autumnal-survey-2016.html

I've people across the range of mobility. Looking at fatigue, there are responses across the scale, and I'll see how this varies with mobility.

Some answers not too surprising: fatigue affects many people's walking and ability to do things requiring physical effort. Many people are shattered by the end of the day, and many who over-do know about it the next day. There is a mild preference for the NFI-MS scale.

Sunday, 6 November 2016

UK HSP 2016 AGM Presentations

Regular readers may have noted that instead of my usual reports from the UK HSP AGM I've posted from the international HSP/Ataxia meeting in Paris, which was on the same weekend. However, I'm also pleased to give details of the presentations given at the AGM. I've lifted these (with permission) from the UK HSP Newlink Newsletter.

Flexyfoot 

Georgie Powell represented this small company and its innovative products.

The main product is a no-slip ferrule for both sticks and crutches. It is a modern design with an easily (and inexpensively) replaceable "foot" which clicks into place. This foot anchors into the ferrule base which remains tightly fixed to the stick or crutch. This approach allows easy replacement of a worn foot. The company also produce and sell several ranges of sticks in both traditional and modern styles. https://www.flexyfoot.com/

Fully researched, designed and now approved by all the relevant certification bodies, Flexyfoot has a strong following in countries around the world. The current UK Health Service is a fragmented place to sell into and each health authority needs to be "sold to" individually. This cost too much time to be worthwhile - thus the company has concentrated its UK sales efforts towards the larger commercial outlets e.g. Boots. Such chains sell the products well, as do many independent mobility stores. The range of products is steadily increasing (more sizes and colours, differing stiffnesses.)

Plans are afoot to recruit staff in the larger foreign markets to promote/facilitate sales.

Coloplast 

Debra Gordon and Lauren Moore represented Coloplast and updated us on some of the products they provide to help with the continence issues that affect many people with HSP. They began by informing us that it was currently World Continence week.

They discussed catheters and catheterisation and surprised many present by how small their latest catheters are for females. The male catheter has to be a certain length in order to work properly.

 They discussed male incontinence and how it can be managed by using a conveen which is a clever system where a sheath is worn and urine flows down a tube which is attached to the sheath and fills up a bag which is usually worn on the lower leg. This system was demonstrated using their dummy who I believe is named Boris.

They also discussed their bowel irrigation system called Peristeen. This equipment allows the user to fill the bowel with water and after a short period of time, the bowel naturally empties itself and can consequently prevent much discomfort.

Further information on what Coloplast can offer can be found on their website: http://www.coloplast.co.uk

Odstock Medical

Dr Paul Taylor provided an update on the present status of the Odstock FES systems. http://www.odstockmedical.com/

The devices provide electrical stimulus to nerves. The nerves then activate muscles. In HSP the most common use is to activate the muscles which raise the foot during walking, thus preventing the foot from "dragging". To achieve this, two pads are attached to the lower leg, and a switch is placed below a heel within a shoe. Once correctly placed, these can be used together with a control unit to supply pulses which activate the muscles.

Smaller and lighter devices were now in use, some of which clip to the leg and contain the pads - this makes the time to set up each day less. The foot switched can now link to the control box wirelessly, which also makes the system easier to use and less obtrusive.

Enough HSP users had now been supplied with the equipment that some measurements were possible showing the effectiveness of the device for HSP specific use. As a general rule it seems that use of FES improved walking speed over a measured distance by about 10%. There was also a corresponding reduction in effort as measured by heart rate.

Some of the patients who get benefit from the device are not able to perform the daily set-up routine themselves due to other physical or mental conditions. A surgical procedure has been developed to implant the electrodes along the relevant nerve. This removes the need to position the pads correctly each day. For these users the devices produce similar benefits to the normal equipment. The cost of the procedure and its invasive nature makes it only appropriate for a small group of individuals.

Amber Meikle-Janney and skiing - "HSP can’t stop me!" 

Amber is now 17 and gave us a video presentation of the ways in which HSP has affected her and how she was developing her skiing skills despite the condition. Although there had been some indications of onset when she was younger, she had been able to develop a love of skiing on holidays. We were shown some short videos of her aged 6 on skis.

Since the condition started to affect her more, she started to look for ways in which she could continue to ski. She found information on-line about the charity Disability Snowsport UK and got in touch. They have helped her to learn how to ski in a seated position on a mono-ski. Time for more videos, this time of Amber as she was learning - lots of footage of crashes, eventually leading to some long runs!!

Amber, with some help from her Mum, then demonstrated her mono-ski by transferring onto it and showing how she can use it to get onto a ski-lift. This is something not for the fainthearted!

Wednesday, 19 October 2016

Research Update

I'm a member of the Research on Motor Neuron Disorders: PLS, HSP/SP, and ALS
Closed group on Facebook. This is a really good group which keeps posting relevant news and information about HSBC.

This post just gives links to some of the information posted recently. I've only posted links to general stories rather than specific HSP studies. Big thanks to Rita Handrich for setting the group up and posting such good stuff.

This report shows that regular stretching boosts cardiovascular fitness if you can't undertake exercise.
http://www.foxnews.com/health/2016/10/18/regular-stretching-may-boost-fitness-those-who-cant-exercise.html

This article describes using VR glasses to identify if people have a neurodegenerative disease (like HSP)
http://www.ltlmagazine.com/news-item/memory-care/augmented-reality-gives-researchers-new-view-neurodegenerative-diseases

This report talks about chronic pain being it's own neurodegenerative disease, noting that there is often no identifiable source.
http://www.ems1.com/opioids/articles/132786048-Why-chronic-pain-is-a-neurodegenerative-disease/

These are some non medicinal techniques you can use to control pain
http://www.health.harvard.edu/pain/6-ways-to-use-your-mind-to-control-pain?utm_source=delivra&utm_medium=email&utm_campaign=GB201601005-Pain&utm_id=268237&dlv-ga-memberid=24603361&mid=24603361&ml=268237

This site reports a touchless catheter, which might be useful for some:
http://www.news-medical.net/news/20161007/Adapta-Medical-receives-FDA-market-clearance-for-touchless-urinary-catheter.aspx

This article talks about care giving, but you need to subscribe to see the full thing.
https://www.scientificamerican.com/article/caregiving-stress-and-beauty-shots-of-the-brain/

This report indicates a link between weight and cognitive function - the higher your BMI, the higher your inflammation, leading to cognitive decline. Key message is maintain your weight to keep your brain on good form.
http://www.medicalnewstoday.com/releases/313570.php



Friday, 7 October 2016

Hidden Costs of Rare Diseases - new report

Regular readers may remember me attending a drug re-purposing conference back in Feb this year

(reported here: http://hspjourney.blogspot.co.uk/2016/04/my-views-on-drug-repurposing-conference.html)

The item that caught my attention was the presentation about the hidden costs of rare diseases. I spotted the other day that Genetic Alliance have published a report on this very topic. The report is here: https://www.geneticalliance.org.uk/media/2502/hidden-costs-full-report_21916-v2-1.pdf, linked from here https://www.geneticalliance.org.uk/news-events/news/hidden-costs-report/.

The report has some main findings:

  • Receiving coordinated care is important for rare disease patients, yet remains a challenge,
  • The full costs and benefits associated with different models of care for rare disease patients are unknown 
  • Patients and families face significant (‘hidden’) costs (both financial and psychosocial) associated with the way that their care is managed
  • There are significant limitations associated with existing data sets for rare diseases 

Whilst this is reported as being a feasibility study, within the report they have talked to various patients and carers, and there are some good observations on the difficulties which patients find, and they set out proposals for further research. They do identify and summarise these costs associated with rare diseases, which are very similar to those I heard in Feburary:

Financial:
Costs associated with appointments: Time off work and reduced income; childcare; travel including petrol, public transport and taxis; parking; food and refreshments; accommodation; sundries; accessible vehicles and transport options.

Other financial costs associated with wider condition management: Private healthcare; childcare and respite; specialist activities and equipment; IT, internet and telephone costs (including paper and printing cost); prescriptions; fees for informal helpers and carers; disruption to employment and income.

Other:
Time: Time off work; time spent coordinating (‘project managing’) care and the various agencies and appointments involved; time spent fighting to access care and support.

Psychosocial, health and well-being: Disruption to schooling, employment and personal time; impact on relationships and social life; isolation; impact on identity and sense of self; living with uncertainty; mental health; fatigue; confidence and self esteem; anxiety and stress associated with appointments. 

Wider family: Costs identified above related to patients, parents and grandparents; siblings and wider support networks.